🇺🇸 FDA

Company profile · Sponsor

Fulcrum

Fulcrum Therapeutics

FULC · NYSE pharma CAMBRIDGE, MA, USA
Pipeline
12
Drugs
0
Patents
8

Quick answer

Fulcrum (FULC) is a pharma company. headquartered in CAMBRIDGE, MA, USA. listed on NYSE. NovaPharmaNews links 12 pipeline programs, 0 drugs, and 8 patents to this profile..

Company facts

Ticker FULC
Exchange NYSE
Company type pharma
Headquarters CAMBRIDGE, MA, USA
SEC CIK 0001680581

Pipeline (12)

Search pipeline →

  1. Losmapimod

    Fulcrum

    Facioscapulohumeral Muscular Dystrophy (FSHD)

    phase 3 small molecule terminated

    2 trials

  2. Losmapimod oral tablet

    Fulcrum

    COVID-19

    phase 3 small molecule terminated

    1 trial

  3. PL1 - Placebo to match losmapimod tablets are tablets for oral administration and visually match the active losmapimod tablets, 15 mg., Losmapimod

    Fulcrum

    Facioscapulohumeral Muscular Dystrophy (FSHD)

    phase 3 small molecule active

    1 trial

  4. ACE393

    Fulcrum

    Campylobacter Infection

    phase 2 mab active

    1 trial

  5. Losmapimod

    Fulcrum

    Facioscapulohumeral Muscular Dystrophy 1 (FSHD1)

    phase 2 small molecule active

    1 trial

  6. Losmapimod

    Fulcrum

    Facioscapulohumeral Muscular Dystrophy 1 (FSHD1)

    phase 2 small molecule active

    1 trial

  7. Losmapimod

    Fulcrum

    Facioscapulohumeral Muscular Dystrophy 1

    phase 2 small molecule terminated

    1 trial

  8. Losmapimod oral tablet

    Fulcrum

    Facioscapulohumeral Muscular Dystrophy (FSHD)

    phase 2 small molecule completed

    1 trial

  9. Pociredir

    Fulcrum

    Sickle Cell Disease

    phase 2 small molecule active

    2 trials

  10. FTX-6058/placebo oral capsule(s)

    Fulcrum

    Healthy Adult Subjects

    phase 1 small molecule completed

    1 trial

  11. Losmapimod 15 mg oral tablet

    Fulcrum

    Healthy Adult Subjects

    phase 1 small molecule completed

    1 trial

  12. Pociredir oral capsule(s)

    Fulcrum

    Sickle Cell Disease

    phase 1 small molecule completed

    1 trial

Patents (8)

Search patents →

  1. US 12109198

    Macrocyclic azolopyridine derivatives as EED and PRC2 modulators

    Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11819554

    Compositions and methods for modulating FMR1 expression

    Expires Mon Nov 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11590111

    Macrocyclic azolopyridine derivatives as EED and PRC2 modulators

    Expires Mon Feb 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11479770

    Use of p38 inhibitors to reduce expression of DUX4

    Expires Mon Oct 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11291659

    P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD

    Expires Mon Mar 31 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10973805

    Macrocyclic azolopyridine derivatives as EED and PRC2 modulators

    Expires Mon Apr 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10537560

    P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD

    Expires Mon Jan 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10342786

    P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD

    Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Fulcrum?

Fulcrum (FULC) is a pharma company. headquartered in CAMBRIDGE, MA, USA. listed on NYSE. NovaPharmaNews links 12 pipeline programs, 0 drugs, and 8 patents to this profile..

What pipeline programs does Fulcrum sponsor?

We track 12 ClinicalTrials.gov-linked programs for Fulcrum, including Losmapimod and 11 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Fulcrum company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.